Related Experiment Videos
Endotoxin is not an essential mediator in toxic shock syndrome
M E Melish1, S Murata, C Fukunaga
1Department of Pediatrics, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu 96826.
Abstract:
The hypothesis that toxic shock syndrome toxin 1 (TSST-1) exerts its deleterious effects in toxic shock syndrome (TSS) primarily by enhancing the lethality of small amounts of endogenous endotoxin derived from mucosal colonization with gram-negative bacteria was assessed by evaluating two means of inactivating endotoxin in rabbit models of TSS. In both of these models, toxins and TSST-1 are allowed to diffuse constantly from a subcutaneous depot. Immunologic inactivation of endotoxin with antiserum to the core lipopolysaccharide did not change the clinical course or mortality among animals infected with live TSS-associated staphylococci or among animals with a subcutaneous depot of TSST-1. Anti-TSST-1 was successful in preventing disease and death in these models. Pharmacologic inactivation of endotoxin by pretreatment or continuous treatment with polymyxin B did not prevent illness or mortality in the toxin depot model. Endotoxin thus appears not to be an essential mediator in TSS, since TSS-like illness develops and progresses despite inactivation of endotoxin in animal model systems that are faithful both physiologically and clinically to TSS in humans.
Insights
Toxic Shock Syndrome Toxin-1 (TSST-1) does not require endotoxin to cause illness. Inactivating endotoxin did not prevent toxic shock syndrome (TSS) in rabbit models, indicating TSST-1 is the primary driver of TSS.
Area of Science:
- Microbiology
- Immunology
- Pathophysiology
Background:
- Toxic Shock Syndrome (TSS) is a severe illness linked to Staphylococcus aureus toxins.
- A key hypothesis suggests Toxic Shock Syndrome Toxin-1 (TSST-1) potentiates endotoxin's effects, leading to TSS.
Purpose of the Study:
- To investigate the role of endotoxin in TSST-1-mediated TSS.
- To determine if inactivating endotoxin prevents TSS development in animal models.
Main Methods:
- Rabbit models of TSS were used, with continuous toxin diffusion from a subcutaneous depot.
- Endotoxin inactivation was achieved through immunologic (antiserum) and pharmacologic (polymyxin B) methods.
- Disease course and mortality were monitored in animals treated with TSST-1 and/or endotoxin inactivation agents.
Main Results:
- Immunologic inactivation of endotoxin did not alter the clinical course or mortality in TSS models.
- Pharmacologic inactivation of endotoxin with polymyxin B also failed to prevent illness or mortality.
- Administration of anti-TSST-1 antibodies successfully prevented disease and death, confirming TSST-1's critical role.
Conclusions:
- Endotoxin is not an essential mediator in the pathogenesis of TSST-1-induced TSS.
- TSST-1 alone is sufficient to cause TSS-like illness, independent of endotoxin presence.
- These findings challenge the endotoxin-enhancement hypothesis in TSS pathogenesis.